Table 2_Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radio

A clinical trial protocol document outlines a randomized, multicenter Phase III study comparing a novel combination therapy to standard care for recurrent or metastatic pancreatic ductal adenocarcinoma. The study, authored by Xin Wang, plans to enroll 198 patients and will assess overall survival as its primary endpoint. The document was last updated on May 13, 2026.

Use Cases

• Analyzing trial design and methodology for a Phase III oncology study based on the detailed protocol description
• Comparing inclusion/exclusion criteria and outcome measures for pancreatic cancer trials based on the described endpoints
• Studying the rationale for combining stereotactic body radiotherapy with checkpoint inhibitors based on the background section

Strengths

• Document provides a complete, structured protocol for a Phase III clinical trial, including background, methods, and outcomes
• Specifics include a target enrollment of 198 patients and clearly defined primary and secondary endpoints

Limitations

• The dataset is a 16.6 KB DOCX file containing a protocol document, not structured patient-level data
• Column-level documentation for any potential data outputs is absent; field semantics must be inferred from the text
• Row count for any potential data tables is unknown

Provenance

Source

Xin Wang

Collection Method

Prospective, randomized, open-label, multicenter Phase III clinical trial protocol

Freshness

Last updated 2026-05-13 04:47:44